Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Why did it get rejected?
It's gone down before I wouldn't hold my breath
I have no clue what is happening but several members of the board are hold overs from the vasogen takeover which makes me wonder if something like that is happening again. We will find out soon anyways.
https://www.thestar.com/business/2009/08/17/ailing_vasogen_to_merge_with_private_firm.html
I think it's. Win if you just stop putting words in my mouth for the day
Conviently I think that poster said someone else told him patient told that person who told him 10:1. Just like how someone tried to put words into my mouth. More BS being spewed.
It's because I never said it.
I posted before. The wording from mnk pr on the sale of its generic division is it doesn't affect partnered drugs. It's only their inhouse ones from the way it's worded.
Their coverage was shit anyways. They've had that $8 target forever and never revised it ever.
So how does a RS change the market cap situation? Because unless there is an exception I'm not aware of, IPCI has 2 requirements to meet to keep its NAS listing.
-25 million Market cap
-$1 Share price.
Right with roughly 31 mil shares and a 20 mil market cap IPCI needs to hit 65-70cents before it even hits the Market cap requirement. And then it still needs to trade at that range for an extended time
A partnership on any of the NDA's should push this over $1.00 I think most agree.
I couldn't tell you the exact process but I do know it's different because it's not a drug itself but it's added to an already approved drug.
Hopefully after this initial trial is done we may get more guidance on the path forward for it.
From my conversations the intent is to license it. They realize the potential applications are far to many.
It's not a RS. I'll be first to eat my words if for some reason it turns out to be but I'd imagine there would be a halt, pr, split and then it would continue to trade. Not just happen.
I can't say forsure what's happening, but I'm sure even management knows a RS doesn't fix the issues.
The people posting it are either idiots or shorts.
Whoever wrote that is an idiot.
UBS Group AG, for the benefit and on behalf of UBS Securities LLC and UBS Financial Services Inc., two-wholly owned subsidiaries of UBS AG to which UBS AG has delegated portions of its performance obligations with respect to the Auction Rate Securities Rights issued by UBS AG to certain clients and pursuant to which the securities reported herein have been purchased from such clients
https://fintel.io/doc/www.sec.gov/Archives/edgar/data/1610520/000119312518189507/d602676dsc13g.htm
Seems that way to me. With Sabby out I wonder if they bought them back from Sabby? They had between 6-7 million shares no? So a private transaction.
Short interest down again
5/31/2018 1,773,498
Doesn't mean they told anyone anything other that what we've all been told. It's getting close to end of 2h and we all anticipate news. So could be preemptive covering.
We'll see. Not holding my breath
Intellipharmaceutics Receives Anticipated Additional Staff Determination Letter from NASDAQ
Download as PDF
June 08, 2018
TORONTO, ON / ACCESSWIRE / June 8, 2018 / Intellipharmaceutics International Inc. (NASDAQ: IPCI; TSX: IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that it has received a letter from Nasdaq Listings Qualification staff (the "Staff") formally notifying the Company that its 180-day grace period for the $1.00 per share bid price requirement period has expiredand that therefore the Company is non-compliant with Nasdaq Listing Rule 5550(a)(2). While the Company understands has the opportunity to provide a submission to the Nasdaq Hearings Panel (the''Panel''), it does not intend to do so since the Company proactively addressed the bid price issue at the hearing held on May 17, 2018, and since Panel has already granted the Company a further extension within which to address the bid price issue.
The Company was first notified by Nasdaq that it failed to comply with the minimum bid price requirement in December 2017. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided 180 calendar days, or until June 4, 2018, to regain compliance with such rule.
As previously reported, at a hearing held by the Panel on May 17, 2018, the Company presented its plan to regain and maintain compliance with Nasdaq's continued listing requirements, including with respect to the minimum bid price and stockholders' equity requirements. By decision dated May 21, 2018, the Panel granted the Company's request for an extension, through September 28, 2018, to evidence compliance with all applicable requirements for continued listing on Nasdaq, including the $1.00 bid price requirement. Accordingly, the Staff's most recent notice should have no impact on the Company's continued listing on Nasdaq at this time. On or before September 28, 2018, the Company must comply with the minimum bid price requirement by having a closing bid price of over US$1.00 for at least ten prior consecutive trading days. The Company must also have by September 28, 2018 a stockholders' equity position of over $2.5 million. Finally, the Company must by that date provide the Panel with updated financial projections demonstrating its ability to maintain compliance with the stockholders' equity rule for the coming year. There is no assurance that the Company will be able to regain compliance with the Nasdaq requirements, or if it does, that the Company will be able to maintain such compliance.
If the shares were purchased on TSX does it change those requirements?
I think the consensus is "show me it works"
Short interest down again but by only a minimal amount.
You're doing the same thing just more subtly.
"No clue why there's any speculation that IPCI's Proof of Concept Human trials will be completed soon with expected results by/b4 the end of June wimusky and all?"
The difference is I'm calling you out directly. The reason why there is "speculation" is because this is what people were told.
Christ you live less than an hour away. There are people who would kill to have the opportunity you have to interact with the company.
Well make more than one attempt to reach the company. You seem pretty dismissive of those who actually have spoken to people at the company.
Who deleted the sticky post at the top?
Well a pop today, pop on podras, ANDA soon hopefully
I was told up to 30 days but generally less.
Those are stock based compensation though right Samsa? Those are.the ones that were just voted on?
If so they should be warrants with a $3.2 strike price
Obviously a racist comment
How much of that is stock bonuses and how much is actual salary?
Where did u find that?
If you're going to buy over several days then why submit several pieces of paperwork. Wait till it's done the file.
Doubt it. Get rid of your oxy product to buy a company who albeit has other tech, but lead product is an oxy product?
If you get the license back but have no one to sell it what value does it have? There is still the potential that sales pick up. No point getting it back if there is no better options.
It's not a large sum of money by no means. But I think if it was all doom and gloom why would you waste any money?
May 11, 2018 (filed on May 11, 2018)
Insider Name:Patient, Andrew
Ownership Type:Direct Ownership
Securities:Common Shares
Nature of Transaction:10 - Acquisition or disposition in the public market
# or value acquired/disposed of:12,775
Price:$0.40
Another purchase. Up to 72,775 on open market